Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Survival, Costs with First-Line Pazopanib Studied

Adv Ther; 2017 Nov; Vogelzang, Pal, Ghate, et al

Elderly patients with renal cell carcinoma (RCC) treated with first-line pazopanib survived longer than those who received sunitinib, according to an analysis involving >1,000 individuals. Pazopanib treatment also resulted in lower costs and utilization. Participants with RCC were ≥65 years of age and started first-line treatment with either pazopanib (n=522) or sunitinib (n=522). Investigators looked at overall survival, costs, and utilization. Among the results:

  • The group taking pazopanib survived an average of 18.2 months, vs 14.6 months in the contingent receiving sunitinib.
  • All-cause costs were ~$8,800 and ~$10,400, respectively.
  • Inpatient costs were ~$1,500 and ~$2,500, respectively.
  • Inpatient admissions and lengths of inpatient stay were lower in the pazopanib group.
Citation:

Vogelzang N, Pal S, Ghate S, et al. Clinical and economic outcomes in elderly advanced renal cell carcinoma patients starting pazopanib or sunitinib treatment: A retrospective Medicare claims analysis. Adv Ther. 2017;34(11):2452-2465. doi:10.1007/s12325-017-0628-2.

This Week's Must Reads

Does Integrated Delivery Treatment Impact Cost? , J Oncol Pract; ePub 2018 Feb 13; Kaye, Min, et al

Anticancer Agent Dose Rounding Cost Impact Assessed, J Oncol Pract; ePub 2018 Feb 5; Fahrenbruch, et al

Employment in Patients with Early-Stage BC Studied , Cancer; ePub 2018 Feb 13; Ekenga, Pérez, et al

Program’s Impact on CRC Screening in Uninsured , Cancer; ePub 2018 Feb 7; Eberth, Thibault, et al

Charting the Landscape of Oncology Pathway Vendors , J Oncol Pract; ePub 2018 Feb 7; Daly, Zon, et al

Must Reads in Renal Cell Carcinoma

Predicting RCC Outcomes After Surgery , Eur Urol; ePub 2018 Feb 2; Leibovich, et al

Partial vs Radical Nephrectomy Impact on Survival , Eur Urol Focus; ePub 2018 Feb 2; Marchioni, et al

Robotic Partial Nephrectomy for Large Renal Masses , BJU Int; ePub 2018 Jan 22; Delto, Paulucci, et al

Trends Examined in the Reporting of RCC Subtypes, Hum Pathol; ePub 2018 Jan 12; Gansler, et al

VEGFR Therapy’s Role in Reducing RCC Progression , Curr Med Res Opin; ePub 2018 Feb 1; Tannir, et al